Induction of long-lasting T cell responses was mirrored by so far relapse-free survival of the patient, indicating, in line with other tumor vaccines17,18, a potential of DNAJB1-PRKACA-based vaccines to combat residual tumor cells. This evidence concerns the gene PRKACA and neoplasm.